Construction of an Immune-Associated Gene-Based Signature in Muscle-Invasive Bladder Cancer

Figure 6

The expression level of AHNAK and NR2F6 in different molecular subtypes of BC. The results indicated that AHNAK was highly expressed in the basal subtype and NR2F6 was highly expressed in the luminal subtype (a, b). Furthermore, MIBC patients with a high IAG-based signature risk score may indicate the feature of a basal subtype (c).

(a)

(b)

(c)